RevBio Receives a $2.2 Million Phase II NIH Grant to Further Develop the Minimally Invasive Use of TETRANITE® to Treat Complex Spine Fractures
This Grant will Advance the Company’s Preclinical Research to Demonstrate an Improvement to the Current Standard of Care for Treating Vertebral Compression Fractures